Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer
February 11 2021 - 4:05PM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”,
“We”, “Our” or “Inotiv”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, today announced the appointment of Greg Beattie as Chief
Operating Officer of the Company, effective February 15, 2021.
Mr. Beattie brings more than 30 years of
contract research experience to the Company, including more than
two decades in operational leadership roles at Charles River
Laboratories, where he drove growth and profitability across
multiple business units. During his career at Charles River
Laboratories, Mr. Beattie held Corporate Vice President positions
leading business units within all three of Charles River
Laboratories’ segments of operations (Discovery and Safety
Assessment, Research Models and Services and Manufacturing
Support). In these roles, Mr. Beattie was responsible for driving
operational performance for divisions with revenue in excess of
$100 million. Among his most significant
accomplishments was leadership of the design, construction and
staffing of one of the largest preclinical facilities in the world
in Reno, Nevada. Mr Beattie also led a new business venture
(Charles River Accelerator and Development Lab), and integrated an
expanding Biologics Testing Solutions business.
Mr. Beattie holds a Bachelor of Science degree
in Biology from McGill University and a Master of Science degree in
Experimental Health Sciences from Université du Quebéc, and
graduated from the Kellog Management Institute program at
Northwestern University. Mr. Beattie held certification as
Diplomate of the American Board of Toxicology (DABT) between 1999
and 2019.
“We continue to attract high-caliber leaders to
our team and look forward to welcoming Greg as another talented
member of Inotiv,” said Robert Leasure, Jr., the Company's
President and Chief Executive Officer. “He is an accomplished
executive with a proven industry track record, and brings extensive
experience in strategic planning, process improvement,
enterprise-wide system implementation, leadership development and
team building.”
Mr. Beattie commented, “I am very excited to
join Inotiv at this pivotal point in its growth trajectory and I
look forward to helping the team drive value-creation for our
stakeholders. Inotiv has a reputation for outstanding talent, a
strong client-service orientation and a winning culture, which
should provide an excellent foundation to continue to build
upon.”
About the Company
Bioanalytical Systems, Inc., doing business as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more information
about the Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact |
|
Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv |
|
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
|
Kalle Ahl, CFA |
(765) 497-8381 |
|
(212) 836-9614 |
btaylor@inotivco.com |
|
kahl@equityny.com |
|
|
|
|
|
Devin Sullivan |
|
|
(212) 836-9608 |
|
|
dsullivan@equityny.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/587eb23f-11a0-4879-a96f-01a4379900fd
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024